Sign in
Companies / CRL vs INCY

CRL vs INCY: Charles River Laboratories International and Incyte

Life Sciences Tools and Biotechnology
Compare more companies

Charles River Laboratories International (CRL) reported $4.0B in revenue against a -3.6% net margin, while Incyte (INCY) reported $5.1B at a 25.0% net margin, most recently.

MetricCRLINCY
Revenue$4.0B$5.1B
Net Income$-0.1B$1.3B
Gross Margin—92.8%
Operating Margin0.6%29.5%
EPS (Diluted)$-2.91$6.41
Free Cash Flow$0.5B—
Total Debt$2.1B—
P/E Ration/m15.4×
P/B Ratio3.2×3.8×
Stock Price$312.87$119.99
Free: last 5 years
Fiscal yearFY2009 🔒FY2010 🔒FY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021FY2022FY2023FY2024FY2025
CRL Revenue••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$3.5B$4.0B$4.1B$4.0B$4.0B
INCY Revenue••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$3.0B$3.4B$3.7B$4.2B$5.1B

More on CRL

More on INCY

Other comparisons